Comparing Wind and Solar Energy Impacts on the Environment: A LCA Approach Using openLCA Platform

Large-scale wind and solar power plants are being developed at a rapid rate, contributing to not only clean energy, but also waste accumulation and other environmental impacts. The environmental issues related to the decommissioning and disposal of such modules have not been addressed comprehensively due to the long life cycle of these products. This study helps to identify and appraise various impacts of their life cycle processes using the ultimate damage indicators of ecosystem quality, human health, and resources. The environmental impacts of a photovoltaic module (solar) and a wind turbine are compared using the life cycle assessment (LCA) method. The comparison established that the wind turbine has smaller environmental impacts in almost all impact categories assessed. The comparison also showed disposal processes can be a major contributor to environmental impacts, depending on the disposal scenario. The results demonstrate that with knowledge of the environmental impacts over the course of the entire life cycle for both wind turbines and solar panels, a proper disposal method would help avoid large quantities of waste and the potential savings can be quite large. Under the circumstances presented in this study, wind turbine energy proved to be more environmentally friendly compared to solar panel energy due to the contribution of certain flows and processes such as land occupation, materials and resources used, and emissions and toxic chemicals released

Diarrhea as a risk factor for acute lower respiratory tract infections among young children in low income settings

Diarrhea and acute lower respiratory tract infections (ALRI) are leading causes of morbidity and mortality among children under 5 years of age. We sought to quantify the correlation of diarrhea and respiratory infections within an individual child and to determine if infection with one illness increases the risk of infection with the other during the same time period

Does comorbidity increase the risk of mortality among children under 3 years of age?

Objectives Diarrhoea and pneumonia remain leading causes of morbidity and mortality in children under 5 years of age. Little data is available to quantify the burden of comorbidity and the relationship between comorbid diarrhoea and pneumonia infections and mortality. We sought to quantify the relationship between comorbidity and risk of mortality among young children in two community-based studies conducted among South Asian children. Design Secondary data analysis of two cohort studies. Participants We identified two cohort studies of children under 3 years of age with prospective morbidity at least once every 2 weeks and ongoing mortality surveillance. Outcome measures We calculated the mortality risk for diarrhoea and acute lower respiratory infection (ALRI) episodes and further quantified the risk of mortality when both diseases occur at the same time using a semiparametric additive model. Results Among Nepali children, the estimated additional risk of mortality for comorbid diarrhoea and ALRI was 0.0014 (−0.0033, 0.0060). Among South Indian children, the estimated additional risk of mortality for comorbid diarrhoea and ALRI was 0.0032 (−0.0098, 0.0162). This risk is in addition to the single infection risk of mortality observed among these children. Conclusions We observed an additional risk of mortality in children who experienced simultaneous diarrhoea and ALRI episodes though the CI was wide indicating low statistical support. Additional studies with adequate power to detect the increased risk of comorbidity on mortality are needed to improve confidence around the effect size estimate

Multimodal and Multifunctional Signaling? – Web Reduction Courtship Behavior in a North American Population of the False Black Widow Spider

Males of widow spiders courting on the web of females engage in web-reduction behavior which entails excising a section of the web, bundling it up, and wrapping it with their silk. Males of the false black widow spider, Steatoda grossa, in European populations also produce stridulatory courtship sound which has not yet been studied in their invaded North American range. Working with a North American population of S. grossa, we tested the hypotheses that (1) web reduction by males renders webs less attractive to rival males; (2) deposition of silk by courting males has an inter-sexual (male-female) signal function that enhances their likelihood of copulation; and (3) stridulatory sound is a courtship signal of males. Testing anemotactic attraction of males in Y-tube olfactometer experiments revealed that reduced webs (indicative of a mated female) and intact webs (indicative of a virgin female) were equally attractive to males. Recording courtship behavior of males with either functional (silk-releasing) spinnerets or spinnerets experimentally occluded on the web of virgin females showed that males with functional spinnerets were more likely to copulate with the female they courted. Although males possess the stridulatory apparatus to produce courtship sound, they did not stridulate when courting or copulating on the web of females. Our data support the conclusion that web-reduction behavior of S. grossa males in their invaded North American range has no long-range effect on mate seeking males. Instead, web-reduction behavior has an inter-sexual signaling function that seems to be linked to functional spinnerets of the courting male. The signal produced by a male likely entails a volatile silk-borne pheromone, but may also embody a gauge of his endurance (the amount of time he engages in web reduction causing web vibrations)

Management of Hypertensive Emergencies in Pediatrics

As hypertension becomes more prevalent in the pediatric population, clinicians are more likely to encounter hypertensive emergencies in children, which require pharmacists and physicians to be educated on the therapeutic options for these emergencies. However, the strict governmental requirements on the testing of these drugs in pediatric patients have limited the amount of available evidence on which to base clinical decisions. This review will highlight the available evidence and preferred treatment options for the management of pediatric hypertensive emergencies

An Update on Gestational Diabetes

Gestational diabetes is a concern for a large number of pregnant women due to the potential for long-term complications for both the mother and the fetus. With the increasing prevalence of obesity and diabetes in the general public, the number of pregnant women with undiagnosed type 2 diabetes mellitus has also increased. In order to adequately educate their patients, it is important for pharmacists to be aware of the general practices of treating gestational diabetes. This review will highlight recent updates to initial screening, the criteria for diagnosing gestational diabetes, and current management strategies

Therapeutic Efficacy of Human Hepatocyte Transplantation in a SCID/uPA Mouse Model with Inducible Liver Disease

Severe Combined Immune Deficient (SCID)/Urokinase-type Plasminogen Activator (uPA) mice undergo liver failure and are useful hosts for the propagation of transplanted human hepatocytes (HH) which must compete with recipient-derived hepatocytes for replacement of the diseased liver parenchyma. While partial replacement by HH has proven useful for studies with Hepatitis C virus, complete replacement of SCID/uPA mouse liver by HH has never been achieved and limits the broader application of these mice for other areas of biomedical research. The herpes simplex virus type-1 thymidine kinase (HSVtk)/ganciclovir (GCV) system is a powerful tool for cell-specific ablation in transgenic animals. The aim of this study was to selectively eliminate murine-derived parenchymal liver cells from humanized SCID/uPA mouse liver in order to achieve mice with completely humanized liver parenchyma. Thus, we reproduced the HSVtk (vTK)/GCV system of hepatic failure in SCID/uPA mice.In vitro experiments demonstrated efficient killing of vTK expressing hepatoma cells after GCV treatment. For in vivo experiments, expression of vTK was targeted to the livers of FVB/N and SCID/uPA mice. Hepatic sensitivity to GCV was first established in FVB/N mice since these mice do not undergo liver failure inherent to SCID/uPA mice. Hepatic vTK expression was found to be an integral component of GCV-induced pathologic and biochemical alterations and caused death due to liver dysfunction in vTK transgenic FVB/N and non-transplanted SCID/uPA mice. In SCID/uPA mice with humanized liver, vTK/GCV caused death despite extensive replacement of the mouse liver parenchyma with HH (ranging from 32-87%). Surprisingly, vTK/GCV-dependent apoptosis and mitochondrial aberrations were also localized to bystander vTK-negative HH.Extensive replacement of mouse liver parenchyma by HH does not provide a secure therapeutic advantage against vTK/GCV-induced cytotoxicity targeted to residual mouse hepatocytes. Functional support by engrafted HH may be secured by strategies aimed at limiting this bystander effect

New ways to turn on NKT cells

Godfrey and Rossjohn discuss the varied ways to turn on NKT cells in the context of recent findings

Diarrhea incidence in low- and middle-income countries in 1990 and 2010: a systematic review

<p>Abstract</p> <p>Background</p> <p>Diarrhea is recognized as a leading cause of morbidity and mortality among children under 5 years of age in low- and middle-income countries yet updated estimates of diarrhea incidence by age for these countries are greatly needed. We conducted a systematic literature review to identify cohort studies that sought to quantify diarrhea incidence among any age group of children 0-59 mo of age.</p> <p>Methods</p> <p>We used the Expectation-Maximization algorithm as a part of a two-stage regression model to handle diverse age data and overall incidence rate variation by study to generate country specific incidence rates for low- and middle-income countries for 1990 and 2010. We then calculated regional incidence rates and uncertainty ranges using the bootstrap method, and estimated the total number of episodes for children 0-59 mo of age in 1990 and 2010.</p> <p>Results</p> <p>We estimate that incidence has declined from 3.4 episodes/child year in 1990 to 2.9 episodes/child year in 2010. As was the case previously, incidence rates are highest among infants 6-11 mo of age; 4.5 episodes/child year in 2010. Among these 139 countries there were nearly 1.9 billion episodes of childhood diarrhea in 1990 and nearly 1.7 billion episodes in 2010.</p> <p>Conclusions</p> <p>Although our results indicate that diarrhea incidence rates may be declining slightly, the total burden on the health of each child due to multiple episodes per year is tremendous and additional funds are needed to improve both prevention and treatment practices in low- and middle-income countries.</p

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial

Background: Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Achieving minimal residual disease (MRD) negativity in CLL is an independent predictor of survival even with a variety of different treatment approaches and regardless of the line of therapy. Methods/design: GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) is a seamless phase II/III, multi-centre, randomised, controlled, open, parallel-group trial for patients with CLL who have recently responded to chemotherapy. Participants will be randomised to receive either obinutuzumab (GA-101) consolidation or no treatment (as is standard). The phase II trial will assess safety and short-term efficacy in order to advise on continuation to a phase III trial. The primary objective for phase III is to assess the effect of consolidation therapy on progression-free survival (PFS). One hundred eighty-eight participants are planned to be recruited from forty research centres in the United Kingdom. Discussion: There is evidence that achieving MRD eradication with alemtuzumab consolidation is associated with improvements in survival and time to progression. This trial will assess whether obinutuzumab is safe in a consolidation setting and effective at eradicating MRD and improving PFS. Trial registration: ISRCTN, 64035629. Registered on 12 January 2015. EudraCT, 2014-000880-42. Registered on 12 November 2014